APRINOIA Therapeutics Email Format

Biotechnology ResearchŌsaka, Japan11-50 Employees

APRINOIA Therapeutics is an Osaka-based biotechnology research company focused on drug discovery and early development grounded in scientific rigor and integrity. The company seeks to create imaging-based diagnostic tools to improve detection, monitoring of progression, and assessment of neurological diseases, alongside novel therapies to treat these conditions. It positions itself within the biotechnology sector as a small- to mid-sized firm pursuing innovative approaches to neurological health.

As part of its neuroscience program, APRINOIA is developing imaging approaches to detect tau pathology, including a PET imaging tracer intended to identify tau aggregates associated with multiple tauopathies. In May 2025 the company launched a contract service to measure high-molecular-weight oligomer tau species using a high-sensitivity ELISA system, expanding its offerings. Based in Osaka, Japan, the firm operates as a small- to mid-sized biotechnology company focused on advancing diagnostics and therapies for neurodegenerative diseases.

Get verified APRINOIA Therapeutics emails free

Company overview Employee directory